# Phase 4 cancer trials recruiting: 195 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 195 trials in phase 4 for cancer that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 4 cancer trials: 195 rows for $9.75, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 6 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-4/neoplasms

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 195
- Recruiting or not yet: 195
- Read on: November 19, 2026

## Trials

The 25 newest of 195, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 6, 2026 | NCT07923162 | MACE and BTK Inhibitors | University Hospital, Caen | Phase 4 | Not yet recruiting | Hematologic Cancer, MACE, BTK Inhibitors | 10,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07923162) |
| November 6, 2026 | NCT07922759 | Lidocaine Infiltration and Neuroimmunomodulation in Head and Neck Cancer Surgery | University Medical Centre Ljubljana | Phase 4 | Recruiting | Head and Neck Cancer (H&N) | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07922759) |
| October 28, 2026 | NCT07901504 | Remimazolam vs Propofol for Motor and Somatosensory Evoked Potentials in Spinal Tumor Surgery | Beijing Tsinghua Chang Gung Hospital | Phase 4 | Not yet recruiting | Spinal Cord Neoplasms, Spinal Neoplasms | 190 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07901504) |
| October 19, 2026 | NCT07881835 | A Phase IV Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma That is Not Responding to Four or... | Pfizer | Phase 4 | Not yet recruiting | Relapsed/Refractory Multiple Myeloma, Multiple Myeloma | 75 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07881835) |
| October 13, 2026 | NCT07872553 | A Study of Treatment Delivery Preference In People With Kidney Cancer | Memorial Sloan Kettering Cancer Center | Phase 4 | Recruiting | Renal Cell Carcinoma, Kidney Cancer | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07872553) |
| October 6, 2026 | NCT07861815 | Assessing the Feasibility of Using Methylene Blue in Identifying Ureters During Colorectal Surgery | Chinese University of Hong Kong | Phase 4 | Not yet recruiting | Colorectal Cancer, Colorectal Surgery, Ureteric Injury | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07861815) |
| October 5, 2026 | NCT07859319 | Evaluation of the Efficacy and Acceptability of a Phytotherapy Combining Devil's Claw, Blackcurrant and Meadowsweet for the Management of... | Hospices Civils de Lyon | Phase 4 | Not yet recruiting | Hormone Therapy-induced Arthralgia, Phytotherapy, Symptom Management, Adjuvant Treatment, Patient Acceptability, Joint... | 105 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07859319) |
| October 5, 2026 | NCT07857655 | Intraoperative Methadone for the Management of Postoperative Pain in Patients With Head and Neck Cancers | OHSU Knight Cancer Institute | Phase 4 | Recruiting | Head and Neck Carcinoma, Hypopharyngeal Carcinoma, Laryngeal Carcinoma, Oral Cavity Carcinoma, Oropharyngeal Carcinoma | 58 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07857655) |
| September 30, 2026 | NCT07848828 | Autonomic and Renal Contributions to Hypertension With ADT | Virginia Commonwealth University | Phase 4 | Recruiting | Androgen Deprivation Therapy, Prostate Cancer, Hypertension, Autonomic Dysfunction, Renal Disease | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07848828) |
| September 25, 2026 | NCT07843134 | Suzetrigine Versus Standard Analgesia After Skin Cancer Surgery | University of Minnesota | Phase 4 | Not yet recruiting | Postoperative Pain, Acute Pain, Skin Cancer, Cutaneous Malignancy, Mohs Surgery | 230 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07843134) |
| September 21, 2026 | NCT07829757 | A Study of Zolbetuximab Given With mFOLFOX6 or CAPOX Chemotherapy in Indian Adults With Gastric Cancer | Astellas Pharma Global Development, Inc. | Phase 4 | Not yet recruiting | Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable... | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07829757) |
| September 16, 2026 | NCT07822880 | A Study of Selpercatinib (LY3527723) in Participants With Rearranged During Transfection (RET)-Altered Cancers in India | Eli Lilly and Company | Phase 4 | Not yet recruiting | Thyroid Neoplasms, Carcinoma, Non-Small-Cell Lung | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07822880) |
| September 3, 2026 | NCT07802847 | Innovative and Cooperative Pathway Integrating Oncogeriatric, Pharmaceutical and Pharmacological Follow-up in Elderly Patients. | Gustave Roussy, Cancer Campus, Grand Paris | Phase 4 | Not yet recruiting | Elderly, Breast Cancer, Lung Cancer, Prostate Cancer, Colon Cancer, Kidney Cancer, Sarcoma | 794 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07802847) |
| September 3, 2026 | NCT07801027 | A Trial of Pembrolizumab With Chemotherapy or Chemoradiotherapy in Participants From India With Different Types of Cancer... | Merck Sharp & Dohme LLC | Phase 4 | Not yet recruiting | Neoplasm Malignant, Gastric Neoplasms, Gastroesophageal Junction Adenocarcinoma, Biliary Tract Carcinoma, Uterine... | 150 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07801027) |
| August 27, 2026 | NCT07790419 | A Prospective, Single-Arm, Open-Label Clinical Study of the Efficacy and Safety of Hepatic Arterial Infusion Chemotherapy Combined With... | Sponsor not shown (see the record) | Phase 4 | Not yet recruiting | Liver Cancer | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07790419) |
| August 20, 2026 | NCT07776821 | An Exploratory Study on the Efficacy and Safety of Enlonstobart Combined With Concurrent Radiotherapy and Chemotherapy Following Induction... | Tianjin Medical University Cancer Institute and Hospital | Phase 4 | Recruiting | Uterine Cervical Neoplasms | 31 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07776821) |
| August 19, 2026 | NCT07772453 | Ferric Carboxymaltose Versus Iron Sucrose for Iron Deficiency Anemia After Radical Gastrectomy for Gastric Cancer | Sponsor not shown (see the record) | Phase 4 | Not yet recruiting | Gastric Cancer (GC), Iron Deficiency Anemia (IDA), Post-Operative Anemia, Radical Gastrectomy | 160 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07772453) |
| August 17, 2026 | NCT07768358 | Tucatinib Continuation Study | Pfizer | Phase 4 | Not yet recruiting | HER2-positive Breast Cancer, Cervical Cancer, Biliary Tract Neoplasms, Urothelial Cancer, Advanced Non-Small Cell Lung... | 175 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07768358) |
| August 14, 2026 | NCT07766122 | Analysis of the Performance of PSMA Emission Tomography in Patients With Prostate Cancer Treated With HIFU | University Hospital, Toulouse | Phase 4 | Not yet recruiting | Prostate Cancer - Recurrent, Prostate Cancer (Diagnosis) | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07766122) |
| August 12, 2026 | NCT07761351 | A Randomized Controlled Trial Comparing Percutaneous CT-Guided Biopsy and Shape-Sensing Robotic-Assisted Bronchoscopy | Intuitive Surgical | Phase 4 | Recruiting | Lung Cancer (Diagnosis), Lung Nodule | 550 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07761351) |
| July 15, 2026 | NCT07704658 | Pralsetinib DDI Study in Patients With Advanced or Metastatic Solid Tumors | Rigel Pharmaceuticals | Phase 4 | Recruiting | NSCLC (Non-small Cell Lung Cancer), Thyroid Cancer, Solid Tumor Malignancies, Advanced Malignancies | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07704658) |
| July 10, 2026 | NCT07695259 | Olaparib+Trastuzumab+Pertuzumab Neoadjuvant for Elderly HER2+ Breast Cancer | Sponsor not shown (see the record) | Phase 4 | Recruiting | Elderly Females, HER2 + Breast Cancer, Neoadjuvant Therapy | 45 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07695259) |
| July 7, 2026 | NCT07687394 | A Phase IV Randomized Trial of Maxigesic® Versus Standard Analgesia After Radical Gastrectomy | Yonsei University | Phase 4 | Not yet recruiting | Stomach Neoplasms, Pain, Postoperative | 160 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07687394) |
| July 1, 2026 | NCT07677566 | 177Lu-PSMA-617 Combined With Darolutamide in Neoadjuvant Treatment of High-risk Localized Prostate Cancer: a Prospective, Single-arm... | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Phase 4 | Not yet recruiting | Prostate Cancer, Prostate Cancer Patients | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07677566) |
| June 17, 2026 | NCT07652515 | A Study to Evaluate the Safety of Dostarlimab in Adult Participants in India With Primary Advanced or Recurrent Endometrial Cancer | GlaxoSmithKline | Phase 4 | Not yet recruiting | Neoplasms, Endometrial | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07652515) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| Fudan University | 6 |
| Ottawa Hospital Research Institute | 4 |
| Memorial Sloan Kettering Cancer Center | 4 |
| Second Affiliated Hospital, Zhejiang University, School of Medicine | 4 |
| University Medical Center Groningen | 3 |
| [GlaxoSmithKline](https://specstream.ai/data/clinical-trials/company/glaxosmithkline) | 3 |
| Helsinki University Central Hospital | 3 |
| Weill Medical College of Cornell University | 3 |
| [Pfizer](https://specstream.ai/data/clinical-trials/company/pfizer) | 3 |
| Brigham and Women's Hospital | 2 |
| Kaohsiung Medical University Chung-Ho Memorial Hospital | 2 |
| The First Affiliated Hospital with Nanjing Medical University | 2 |
| Tanta University | 2 |
| Peking University Cancer Hospital & Institute | 2 |
| [Rigel Pharmaceuticals](https://specstream.ai/data/clinical-trials/company/rigel-pharmaceuticals) | 2 |
| Gustave Roussy, Cancer Campus, Grand Paris | 2 |
| University of Miami | 2 |
| Mayo Clinic | 2 |
| Yonsei University | 2 |
| OHSU Knight Cancer Institute | 2 |
| [Novartis Pharmaceuticals](https://specstream.ai/data/clinical-trials/company/novartis-pharmaceuticals) | 2 |
| Tianjin Medical University Cancer Institute and Hospital | 2 |
| I.R.C.C.S. Fondazione Santa Lucia | 1 |
| Brazilian Institute of Robotic Surgery | 1 |
| Beijing Chao Yang Hospital | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 50 |
| China | 41 |
| France | 13 |
| Canada | 12 |
| Netherlands | 11 |
| Spain | 9 |
| Germany | 7 |
| Italy | 6 |
| South Korea | 6 |
| Denmark | 5 |
| Norway | 5 |
| United Kingdom | 5 |
| Finland | 4 |
| Taiwan | 4 |
| Sweden | 4 |
| Egypt | 3 |
| Switzerland | 3 |
| Croatia | 3 |
| India | 3 |
| Poland | 3 |
| Brazil | 2 |
| Belgium | 2 |
| Puerto Rico | 2 |
| Slovenia | 2 |
| Russia | 2 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [American restaurants in the United States](https://specstream.ai/data/businesses/american-restaurants/united-states)
- [Public schools in the United States](https://specstream.ai/data/businesses/public-schools/united-states)
- [Inns in the United States](https://specstream.ai/data/businesses/inns/united-states)
- [Contract law firms in the United States](https://specstream.ai/data/businesses/contract-law-firms/united-states)
- [West African restaurants in the United States](https://specstream.ai/data/businesses/west-african-restaurants/united-states)
- [Plastic injection molders in the United States](https://specstream.ai/data/businesses/plastic-injection-molders/united-states)
